Introduction
Although hyperkalaemia is a recognized complication of many potassium-sparing diuretics (Greenblatt and Koch-Weser, 1973; Neale, Lynn and Bailey, 1976; Bailey, 1978) , the development of severe acidosis with these drugs in man has received far less attention. Recently 6 cirrhotic patients who developed reversible metabolic acidosis during treatment with spironolactone were described (Gabow, Moore and Schrier, 1979) . A man is reported who developed significant metabolic acidosis whilst taking Moduretic (amiloride and hydrochlorthiazide). The authors further believe that this is the first patient who has had his whole body potassium measured while hyperkalaemic as a result of this drug.
Case report
In June 1978 an 80-year-old man was referred with a 2-month history of intermittent falling without apparent injury. The falls had started after discharge home following an uneventful transurethral prostatectomy for benign prostatic hypertrophy. There was a 17-year history of rheumatoid arthritis, the symptoms of which were controlled with indomethacin in a total daily dose of 150 mg. He 
Discussion
The risk of hyperkalaemia with potassium-sparing diuretics is well recognized (Greenblatt and KochWeser, 1973; Neale et al., 1976) . Spironolactone has been most frequently implicated and to a lesser extent, also triamterene and amiloride (Bailey, 1978) . In one study (Neale et al., 1976) (Goodman and Gilman, 1975) . In general it is believed that when amiloride is combined with a thiazide, as in Moduretic, the natriuretic effect of the 2 drugs is additive and the amiloride antagonizes potassium excretion. Hyperkalaemia is thus likely to occur and this is especially so in patients with impaired renal function. However, the evidence in this case does not support this view. It would appear that amiloride had a profound action on renal hydrogen ion transport leading to metabolic acidosis. It did not increase the total amount of potassium in the body but the severe hyperkalaemia was probably due to a shift of potassium ion from inside the cells to the plasma. It is well known that this shift occurs in the presence of severe acidosis (Black, 1972) . It is also possible that hyperkalaemia might in turn suppress renal ammonium excretion and accentuate the metabolic acidosis (Tannen, 1977) . Since no study of whole body potassium in relation to potassium-sparing diuretics has been reported the mechanism by which these drugs cause hyperkalaemia merits further investigation.
One complicating factor in this case is the concurrent use of indomethacin, a potent prostaglandin synthesis inhibitor. It has recently been suggested that impaired renal prostaglandin production contributes to the pathogenesis of hyporeninaemic hypoaldosteronism (Norby et al., 1978) 
